182 related articles for article (PubMed ID: 34299067)
21. Chronobiological activity of cysteinyl leukotriene receptor 1 during basal and induced autophagy in the ARPE-19 retinal pigment epithelial cell line.
Koller A; Preishuber-Pflügl J; Runge C; Ladek AM; Brunner SM; Aigner L; Reitsamer H; Trost A
Aging (Albany NY); 2021 Dec; 13(24):25670-25693. PubMed ID: 34919533
[TBL] [Abstract][Full Text] [Related]
22. Ameliorating effect of leukotriene receptor antagonist in multi-organ toxicity induced in rat offspring, a possible role for epidermal growth factor.
Abdelzaher WY; Rofaeil RR; Abdel-Hafez SMN; Atta M; Bahaa El-Deen MA; Ali DM
Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):183-191. PubMed ID: 33504223
[No Abstract] [Full Text] [Related]
23. Montelukast, a Cysteinyl Leukotriene Receptor 1 Antagonist, Induces M2 Macrophage Polarization and Inhibits Murine Aortic Aneurysm Formation.
Kawai Y; Narita Y; Yamawaki-Ogata A; Usui A; Komori K
Biomed Res Int; 2019; 2019():9104680. PubMed ID: 31263710
[TBL] [Abstract][Full Text] [Related]
24. Effects of montelukast, a cysteinyl-leukotriene type 1 receptor antagonist, on the pathogenesis of bleomycin-induced pulmonary fibrosis in mice.
Shimbori C; Shiota N; Okunishi H
Eur J Pharmacol; 2011 Jan; 650(1):424-30. PubMed ID: 21034736
[TBL] [Abstract][Full Text] [Related]
25. The anti-asthmatic drug, montelukast, modifies the neurogenic potential in the young healthy and irradiated brain.
Eriksson Y; Boström M; Sandelius Å; Blennow K; Zetterberg H; Kuhn G; Kalm M
Cell Death Dis; 2018 Jul; 9(7):775. PubMed ID: 29991719
[TBL] [Abstract][Full Text] [Related]
26. Montelukast, cysteinyl leukotriene receptor 1 antagonist, inhibits cardiac fibrosis by activating APJ.
Wu Y; Cui C; Bi FF; Wu CY; Li JR; Hou YM; Jing ZH; Pan QM; Cao M; Lv LF; Li XL; Shan HL; Zhai X; Zhou YH
Eur J Pharmacol; 2022 May; 923():174892. PubMed ID: 35358494
[TBL] [Abstract][Full Text] [Related]
27. The anti-inflammatory effect of montelukast, a cysteinyl leukotriene receptor-1 antagonist, against estradiol-induced nonbacterial inflammation in the rat prostate.
Said MM; Bosland MC
Naunyn Schmiedebergs Arch Pharmacol; 2017 Feb; 390(2):197-205. PubMed ID: 27909742
[TBL] [Abstract][Full Text] [Related]
28. Antiviral activity against Middle East Respiratory Syndrome coronavirus by Montelukast, an anti-asthma drug.
Gan HJ; Harikishore A; Lee J; Jeon S; Rajan S; Chen MW; Neo JL; Kim S; Yoon HS
Antiviral Res; 2021 Jan; 185():104996. PubMed ID: 33309540
[TBL] [Abstract][Full Text] [Related]
29. Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma.
De Lepeleire I; Reiss TF; Rochette F; Botto A; Zhang J; Kundu S; Decramer M
Clin Pharmacol Ther; 1997 Jan; 61(1):83-92. PubMed ID: 9024176
[TBL] [Abstract][Full Text] [Related]
30. Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma.
Reiss TF; Altman LC; Chervinsky P; Bewtra A; Stricker WE; Noonan GP; Kundu S; Zhang J
J Allergy Clin Immunol; 1996 Sep; 98(3):528-34. PubMed ID: 8828530
[TBL] [Abstract][Full Text] [Related]
31. A review of montelukast in the treatment of asthma and allergic rhinitis.
Nayak A
Expert Opin Pharmacother; 2004 Mar; 5(3):679-86. PubMed ID: 15013935
[TBL] [Abstract][Full Text] [Related]
32. The Leukotriene Receptor Antagonist Montelukast Attenuates Neuroinflammation and Affects Cognition in Transgenic 5xFAD Mice.
Michael J; Zirknitzer J; Unger MS; Poupardin R; Rieß T; Paiement N; Zerbe H; Hutter-Paier B; Reitsamer H; Aigner L
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803482
[TBL] [Abstract][Full Text] [Related]
33. Leukotriene C4 induces bronchoconstriction and airway vascular hyperpermeability via the cysteinyl leukotriene receptor 2 in S-hexyl glutathione-treated guinea pigs.
Yonetomi Y; Sekioka T; Kadode M; Kitamine T; Kamiya A; Matsumura N; Fujita M; Kawabata K
Eur J Pharmacol; 2015 May; 754():98-104. PubMed ID: 25704617
[TBL] [Abstract][Full Text] [Related]
34. [Effects of agonist and antagonist of cysteinyl leukotriene receptors on differentiation of rat glioma C6 cells].
Cai BL; Wang XX; Yu SY; Huang XQ; Zhang XY; Fang SH; Lu YB; Zhang WP; Wei EQ
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2011 Mar; 40(2):139-44. PubMed ID: 21488208
[TBL] [Abstract][Full Text] [Related]
35. Cysteinyl leukotriene receptor antagonism: a promising pharmacological strategy for lowering the severity of arthritis.
Venugopal N; Acharya P; Zarei M; Talahalli RR
Inflammopharmacology; 2019 Oct; 27(5):923-931. PubMed ID: 31309487
[TBL] [Abstract][Full Text] [Related]
36. Montelukast.
Markham A; Faulds D
Drugs; 1998 Aug; 56(2):251-6; discussion 257. PubMed ID: 9711449
[TBL] [Abstract][Full Text] [Related]
37. Leukotriene receptor antagonism with montelukast as a possible therapeutic for venous thromboembolism prophylaxis: An observational study.
Sutton SS; Magagnoli J; Cummings TH; Hardin JW
Prostaglandins Other Lipid Mediat; 2022 Aug; 161():106649. PubMed ID: 35595009
[TBL] [Abstract][Full Text] [Related]
38. Leukotrienes induce the migration of Th17 cells.
Lee W; Su Kim H; Lee GR
Immunol Cell Biol; 2015; 93(5):472-9. PubMed ID: 25512344
[TBL] [Abstract][Full Text] [Related]
39. Characterization of cysteinyl leukotriene-related receptors and their interactions in a mouse model of asthma.
Trinh HKT; Suh DH; Nguyen TVT; Choi Y; Park HS; Shin YS
Prostaglandins Leukot Essent Fatty Acids; 2019 Feb; 141():17-23. PubMed ID: 30661601
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of cysteinyl LT1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosis.
Matsuyama M; Hayama T; Funao K; Kawahito Y; Sano H; Takemoto Y; Nakatani T; Yoshimura R
Oncol Rep; 2007 Jul; 18(1):99-104. PubMed ID: 17549353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
